Development of oncolytic virotherapy for the treatment of oral cancer – At the waiting stage for clinical use
Development of oncolytic virotherapy for the treatment of oral cancer – At the waiting stage for clinical use
复制标题
DOI：
10.1016/s1348-8643(16)30016-7
复制
发表时间：
2017
影响因子：
0.5
通讯作者：
Y. Yura;M. Hamada
中科院分区：
文献类型：
--
作者：
Y. Yura;M. Hamada
溶瘤病毒疗法起源于发现病毒感染的肿瘤细胞被病毒的细胞病变效应破坏。肿瘤组织中由病毒感染诱导的细胞死亡也促进癌症患者的固有肿瘤免疫。通过体外和体内研究以及临床试验，已经提出了几种DNA和RNA病毒作为这种治疗的候选者。口腔癌常伴有淋巴结转移，导致患者病情加重。一些溶瘤病毒已被研究其对晚期头颈癌（包括口腔癌）患者的治疗效果。溶瘤病毒疗法有望成为控制放化疗耐药口腔癌的重要治疗手段。
Oncolytic virotherapy originated from the finding that virus-infected tumor cells are destroyed by the cytopathic effects of viruses. Cell death induced by viral infections in tumor tissues also promotes inherent tumor immunity in cancer patients. Several DNA and RNA viruses have been proposed as candidates for this treatment throughin vitroandin vivostudies as well as clinical trials. Oral cancer is often accompanied by lymph node metastasis, resulting in worse patient prognoses. Some oncolytic viruses have been investigated for their therapeutic effects on patients with advanced head and neck cancer, including oral cancer. Oncolytic virotherapy is expected to become a treatment modality that will be essential for controlling chemoradio-resistant oral cancer.